Cartalax vs Pinealon
Two organ-targeted siblings from the same speculative research lineage as Epitalon — built on the same disputed mechanism, aimed at completely different tissue, and backed by two very different (but both thin) evidence bases.
Neither is currently stocked by KYIN Peptides, but both are available to order — see availability below.
At a Glance
| Cartalax | Pinealon | |
|---|---|---|
| Category | Longevity & Cellular Health | Cognitive & Nootropic |
| Molecular class | Tripeptide (Ala-Glu-Asp) | Tripeptide (Glu-Asp-Arg) |
| Research lineage | Khavinson bioregulator family (same as Epitalon) | Khavinson bioregulator family (same as Epitalon and Cartalax) |
| Target tissue | Cartilage (chondrocytes) | Brain (cortical cells, via PEPT2 transporter across the blood-brain barrier) |
| Proposed mechanism | Chromatin binding → cartilage matrix gene transcription (type II collagen, aggrecan, link protein) | DNA regulatory-region binding → gene expression modulation linked to oxidative stress and cognitive aging |
| Evidence base | Weak — no PubMed-indexed cartilage endpoint; central claim from one unreplicated Russian-language animal study | Preclinical only — rodent and cell-culture data, but concentrated within a single research group |
| Human trials | None | None |
| Available from KYIN Peptides | Available to order (not stocked) | Available to order (not stocked) |
The Shared Mechanism
Both compounds descend from Vladimir Khavinson's peptide bioregulator research program, the same lineage that produced Epitalon. Bioregulator peptides in this family are proposed to work by binding chromatin or DNA regulatory regions directly within a specific tissue and influencing gene transcription there — a fundamentally different proposed mechanism from the receptor-agonist pathways used by most other compounds referenced on this site. Cartalax is theorized to bind chromatin in chondrocytes and activate transcription of cartilage matrix genes. Pinealon is theorized to cross the blood-brain barrier via the PEPT2 peptide transporter and bind DNA regulatory regions in cortical cells, modulating gene expression linked to oxidative stress and cognitive aging. Same hypothesis, same research tradition — just pointed at two entirely different organs.
How the Evidence Differs
Cartalax has the thinner case of the two. The chondrocyte-proliferation finding most often cited in its favor comes from a single, unreplicated Russian-language animal experiment outside PubMed, and no PubMed-indexed paper mentioning Cartalax has measured a cartilage-specific endpoint directly. See its full research profile.
Pinealon has more published data behind it — studies report improved learning and memory performance in aged rats, reduced reactive oxygen species and lipid peroxidation in neuronal tissue, and preserved mitochondrial membrane potential under oxidative stress, hypoxia, and ischemia. But all of it is preclinical, and concentrated within a single research group rather than independently replicated elsewhere. No human clinical trial has been conducted for either compound. See Pinealon's full research profile.
Why They're Compared
Cartalax and Pinealon aren't substitutes for each other — nobody researching cartilage biology is choosing between the two the way they might choose between BPC-157 and TB-500. The comparison is useful for a different reason: they're a clean test case for the same underlying, disputed hypothesis (direct peptide-DNA binding as a mechanism of tissue-specific gene regulation) applied to two unrelated organs. Researchers evaluating the Khavinson bioregulator family's broader plausibility often end up looking at more than one member of it side by side, which is where this comparison is actually useful — not as a "which one" decision, but as a "how consistent is the evidence across the family" one.
Availability
Neither Cartalax nor Pinealon is part of KYIN Peptides' standard catalogue, but both are available to order — contact us directly and we'll source them for you.
Cartalax vs Pinealon questions
What do Cartalax and Pinealon have in common?
Both are short synthetic tripeptides from the same Khavinson bioregulator research lineage as Epitalon, and both are proposed to work the same way — by binding chromatin or DNA regulatory regions directly in a specific tissue and influencing gene transcription there, rather than acting through a conventional cell-surface receptor. Cartalax targets cartilage-forming chondrocytes; Pinealon targets cortical brain tissue.
Which has stronger evidence, Cartalax or Pinealon?
Neither has strong evidence, but the gaps differ. Cartalax's central supporting claim comes from a single, unreplicated Russian-language animal experiment outside PubMed, and no PubMed-indexed paper mentioning it has measured a cartilage-specific endpoint. Pinealon has more published preclinical data — rodent and cell-culture studies on learning, memory, and oxidative stress — but it all comes from a single research group, and no human trial has been conducted for either compound.
Does KYIN Peptides sell Cartalax or Pinealon?
Neither is part of our standard catalogue, but both are available to order — contact us directly and we'll source them for you.
Interested in sourcing Cartalax or Pinealon?
Contact us and we'll help you source either, or browse the compounds KYIN stocks from the same research lineage.